Actinium Pharmaceuticals, Inc. ATNM
Set alert
As of Nov 2, 9:55 AM ET
- YTD
- +8.46%
- 1 year
- +3.15%
- Open
- 1.48
- Prev close
- 1.50
- Mkt cap
- 46.38M
- Vol
- 9.25K
- Avg vol
- 188.97K
- EPS
- 0.36
- P/E
- 4.10
- Div yield
- 0.00%
More statistics
- Low
- 1.45
- High
- 1.49
- Forward P/E
- -1.77
- Beta
- 0.15
- Short ratio
- 5.72
- Inst. own
- 30.11%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.55
- 200-d avg
- 4.86
- 1y target
- 5.00
News
1 hour ago prnewswire.com
Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models
Poster presentation to highlight preclinical efficacy of ATNM-400 across therapy-resistant breast cancer subtypes ATNM-400 is a first-in-class targeted alpha therapy directed against HER3, a driver…
2 days ago prnewswire.com
Actinium Pharmaceuticals Announces Inducement Grant to New Employee
NEW YORK, Oct. 30, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an…
5 days ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…
-
1 week ago benzinga.com
Actinium Pharma To Present First‑In‑Human Phase 1 Study Of ATNM‑400, HER3-Targeted, Non-PSMA Radiotherapy, In Metastatic Castration‑Resistant Prostate Cancer, At ESMO Congress 2026
First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy…
1 week ago prnewswire.com
Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026
First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy…
1 week ago defenseworld.net
Contrasting Actinium Pharmaceuticals (NYSE:ATNM) and Cytokinetics (NASDAQ:CYTK)
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Cytokinetics (NASDAQ: CYTK - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two…
1 week ago benzinga.com
Why Is Actinium Pharmaceuticals Stock Gaining Tuesday?
Actinium Pharmaceuticals shares jump 9% after positive Phase 1 ATNM-400 trial results in prostate cancer show early safety and retention.
1 week ago prnewswire.com
Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer
HER3‑targeted PET imaging demonstrated tumor uptake and retention, supporting ATNM‑400's potential to deliver sustained alpha radiation to tumors over a timeframe consistent with Actinium‑225's…
-
1 week ago benzinga.com
Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new…
1 week ago prnewswire.com
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models
ATNM-400 demonstrated activity across EGFR-, KRAS- and ALK-driven lung cancer models, supporting mutation-agnostic development as monotherapy and in combination with established treatments In…
1 week ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX)…
-
2 weeks ago benzinga.com
Actinium Pharmaceuticals To Present Data And Preclinical Results For ANTM-400 At The Congress Of The European Association Of Nuclear Medicine, October 17–21
First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMAPreclinical presentation to…
2 weeks ago prnewswire.com
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026
First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMA Preclinical presentation to…
2 weeks ago prnewswire.com
Actinium Pharmaceuticals Announces Inducement Grants to New Employees
NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced…
-
2 weeks ago benzinga.com
Actinium Pharma To Present Preclinical Data Supporting ATNM-400's Broad Potential At 39th Annual Congress Of EANM
Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal…
2 weeks ago prnewswire.com
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models
Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal…
2 weeks ago prnewswire.com
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development
– Brings more than 20 years of oncology business development and commercial leadership, including senior roles across the radiopharmaceutical sector at Bayer, Clovis Oncology, Telix Pharmaceuticals…
-
2 weeks ago benzinga.com
Actinium Pharmaceuticals To Present Early Phase 1 Clinical Data For ATNM-400 In Metastatic Prostate Cancer At EANM 2026
Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation…
2 weeks ago prnewswire.com
Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer
Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation…
-
2 weeks ago benzinga.com
Actinium Pharmaceuticals Appoints Dr. Matt David As CFO
Dr. David brings more than two decades of experience across biopharmaceutical operating leadership, healthcare investment banking and equity research. He joins Actinium from CorMedix Inc.…
2 weeks ago prnewswire.com
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced…
1 month ago defenseworld.net
Reviewing Praxis Precision Medicines (NASDAQ:PRAX) & Actinium Pharmaceuticals (NYSE:ATNM)
Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) and Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) are both healthcare companies, but which is the superior business? We will…
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…
1 month ago prnewswire.com
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that…
-
2 months ago benzinga.com
Actinium Pharmaceuticals Advances Actimab-A Program With New Patents, Expanded Manufacturing Capacity And Clinical Milestones Into 2027
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including…
-
2 months ago benzinga.com
Actinium Pharmaceuticals Receives NYSE American Compliance Plan Acceptance, Granted Until Nov. 27, 2027 To Regain Listing Compliance
American LLC ("NYSE American") that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide (the "Company
2 months ago prnewswire.com
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced…
-
2 months ago benzinga.com
Actinium Pharmaceuticals Q2 EPS $0.89 Beats $(0.21) Estimate, Sales $35.000M
Actinium Pharmaceuticals (AMEX:ATNM) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $(0.21) by 523.81 percent. This is a 504.55 percent increase over…
3 months ago defenseworld.net
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. Actinium Pharmaceuticals (NYSE:ATNM) Financial Contrast
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both small-cap medical companies, but which is the better business? We…
3 months ago defenseworld.net
Palatin Technologies (OTCMKTS:PTNT) and Actinium Pharmaceuticals (NYSE:ATNM) Head to Head Review
Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Palatin Technologies (OTCMKTS:PTNT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will…
-
5 months ago benzinga.com
Actinium's ATNM-400 Reports Preclinical Activity And Combination Synergy Across KRAS- And EGFR-Mutant NSCLC, Supporting Mutation-Agnostic Potential
New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater…
5 months ago prnewswire.com
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater…
-
5 months ago benzinga.com
Actinium Pharma Presents New Data On ATNM-400 In Prostate Cancer At SNMMI 2026 Annual Meeting
New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi®), apalutamide…
5 months ago prnewswire.com
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi®), apalutamide…
5 months ago prnewswire.com
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical…
-
5 months ago benzinga.com
Actinium Pharmaceuticals Obtains Two Patent Allowances Spanning Its Actimab-A And Iomab-ACT Programs
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Canadian Intellectual Property Office (CIPO) has…
-
5 months ago benzinga.com
Actinium Pharmaceuticals To Reveal ATNM-400 Program Update At SNMMI 2026 Conference on May 31-June 2; Co. Receives NYSE Noncompliance Notice
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced it will provide a program update on its first-in-class…
-
6 months ago benzinga.com
Actinium Highlights Data Presented At AACR Supporting Transcriptional Reprogramming As Central Mechanism Driving Mutation-Agnostic Anti-Leukemic Activity Of Actimab-A In AML
Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies…
-
6 months ago benzinga.com
Actinium Pharma Presents Preclinical Results For ATNM-400 Across Prostate, Lung, And Breast Cancer Models Presented At AACR Annual Meeting
ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potentialIn prostate cancer, ATNM-400 demonstrates efficacy across…
-
7 months ago benzinga.com
Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target
Stephens & Co. analyst Sudan Loganathan reiterates Actinium Pharma (AMEX:ATNM) with a Overweight and maintains $5 price target.
-
8 months ago benzinga.com
Actinium To Present Abstracts On ATNM-400 And Actimab-A Programs Across Solid Tumors And Hematologic Oncology Applications At AACR Annual Meeting 2026
AACR Presentations to Feature ATNM-400 and Actimab-A Programs Across Solid Tumors and Hematologic Oncology ApplicationsNEW YORK, Feb. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
2 years ago benzinga.com
Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Nasdaq Tumbles 3%; Tyson Foods Earnings Top Views
Nasdaq Tumbles 3%; Tyson Foods Earnings Top Views
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 647 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 369 companies set new 52-week lows.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
-
3 years ago benzinga.com
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on…